London Stock Exchange · Healthcare
Invest in Shield Therapeutics stock from India
Indian and foreign residents can buy Shield Therapeutics (STX) shares directly through Paasa.
By Paasa · Updated
Shield Therapeutics at a glance
- Price
- £0.06+£0.00 (5.36%)
- Market cap
- £63.10M
- Day range
- £0.06 – £0.06
- P/E
- -8.00
- Dividend yield
- None
- Volume
- 2.62M
- 1 month
- -3.28%
- 6 months
- -26.25%
- YTD
- -40.10%
- 1 year
- -16.31%
- 5 years
- -85.06%
Shield Therapeutics statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $50.7M | $32.2M | $16.5M | $4.5M | $1.5M |
| Gross profit | $22.4M | $13.2M | $5.1M | $2.0M | −$1.7M |
| Operating income | −$10.3M | −$22.9M | −$31.3M | −$26.4M | −$20.4M |
| Net income | −$18.0M | −$26.6M | −$33.3M | −$40.4M | −$19.3M |
| Earnings per share | −$0.02 | −$0.03 | −$0.05 | −$0.17 | −$0.09 |
| EBITDA | −$9.2M | −$21.3M | −$38.3M | −$46.1M | −$17.7M |
| Total assets | $65.2M | $57.4M | $48.8M | $22.1M | $44.4M |
| Total debt | $30.1M | $26.3M | $25.8M | $6.1M | $156.0K |
| Cash and short-term investments | $11.6M | $7.0M | $17.6M | $2.8M | $12.1M |
| Shareholders' equity | −$15.1M | −$1.3M | $11.8M | $5.4M | $40.7M |
| Operating cash flow | −$8.8M | −$8.8M | −$46.9M | −$18.2M | −$16.7M |
| Free cash flow | −$8.8M | −$8.8M | −$50.7M | −$20.1M | −$18.8M |
| Capital expenditure | −$24.5K | −$34.3K | −$3.7M | −$1.9M | −$2.1M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| INSPECS | SPEC.L | £0.92 | £100.44M |
| Scancell | SCLP.L | £0.09 | £97.55M |
| Venture Life | VLG.L | £0.65 | £79.19M |
| ECO Animal Health | EAH.L | £0.98 | £65.38M |
| Ondine Biomedical | OBI.L | £0.10 | £50.54M |
| Creo Medical | CREO.L | £0.10 | £49.55M |
| BATM Advanced Communications | BVC.L | £0.11 | £37.17M |
| Hemogenyx Pharmaceuticals | HEMO.L | £4.61 | £31.32M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Shield Therapeutics from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to GBP when you buy.
Step 3
Search STX and buy
Find Shield Therapeutics by name or by its ticker, STX, and place your order.
Why invest in Shield Therapeutics from India
What Shield Therapeutics does
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Here's what inheritance rules in the UK mean for your Shield Therapeutics shares.
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents.
Frequently asked questions
Can I buy Shield Therapeutics stock from India?
Yes. Indian residents and NRIs can buy Shield Therapeutics (STX) shares directly through Paasa. Shield Therapeutics is listed on the London Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
How are Shield Therapeutics dividends taxed for Indian investors?
Shield Therapeutics does not currently pay a dividend, so there is nothing to withhold or declare today. If it starts paying one, the UK levies 0% withholding tax on company dividends paid to non-residents, and dividends are taxed at your slab rate in India.
What tax do I pay in India when I sell Shield Therapeutics shares?
Non-residents are exempt from UK capital gains tax on the disposal of listed shares. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the GBP/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
What happens to my Shield Therapeutics shares if I pass away?
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents. The rule looks at everything you hold there, not at Shield Therapeutics alone.
Is there stamp duty when I buy Shield Therapeutics shares?
The UK charges 0.5% Stamp Duty Reserve Tax when buying direct company shares electronically on the LSE; ETFs and UCITS funds do not attract it.